Casodex

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c8001) has announced the addition of Prostate Cancer Insight - Profiting From Changing Treatment Patterns to their offering

Prostate cancer is the most common male malignancy in Western countries.

Wider use of screening and changes in treatment practice will force companies to adapt their products and marketing goals.

These changes will occur over the next five years, but manufacturers must implement new business plans now to capitalize on the effects of stage migration at diagnosis and new treatment approaches.

Scope of report:

--Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

--Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

--Coverage of the hot topics affecting current treatment patterns, from the impact of Imrt on brachytherapy to the increasing use of bisphosphonates

--A strong future focus on key issues, including the increasing use of third generation cytotoxics in Hrpc and the implementation of screening in Europe

Report Highlights

AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an Lhrh agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of Lhrh agonists.

In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. This report shows that the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis' Taxotere show much greater efficacy and usage of this combination is already significant.

Reasons to Purchase Report:

--Identify hot topics and key issues for practicing prostate cancer specialists - the questions they really want answered

--Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice

--Plan product development to fill prostate cancer market niches as defined by practicing physicians

Casodex 150mg withdrawn for the treatment of localized disease 3

Chapter 1 EXECUTIVE SUMMARY 4

Prostate Cancer Insight: methodology 5

Prostate Cancer Insight: key conclusions 6

The widespread introduction of PSA screening in Europe will occur over the next 10 years, leading to a US-style stage migration. Companies with marketed or developmental prostate cancer products must target the larger localized and recurrent disease populations that will result 7

Traditionally, total androgen blockade (TAB) has been shunned by urologists. However, new literature reviews are now challenging physicians' preconceptions and changing prescribing habits in favor of TAB, producing a niche market for low toxicity anti-androgens 11

The average age of Japanese patients is higher than in Western markets. This means that aggressive therapy is often contraindicated. Consequently, more patients receive drug-based therapy, producing a deceptively large drug market that should be targeted by manufacturers 15

Intermittent hormonal therapy (IHT) may provide an improvement in efficacy and side effects over continuous hormonal therapy. Manufacturers of hormonal products must consider how they may capitalize on the uptake of IHT if current trials show an advantage to the new treatment strategy 16

Taxotere is becoming the treatment of choice for hormone refractory prostate cancer (HRPC). Companies with products in development for HRPC should assess their products in combination with the taxane 21

Summary of points: the prostate cancer market to 2015 23

Chapter 2 INTRODUCTION 32

Chapter 3 SCREENING, DIAGNOSIS AND STAGING 41

Chapter 4 TREATMENT OF LOCALIZED DISEASE 66

Chapter 5 TREATMENT OF LOCALLY ADVANCED DISEASE 150

Chapter 6 TREATMENT OF METASTATIC DISEASE 189

Chapter 7 TREATMENT OF HRPC 241

Chapter 8 SIDE EFFECTS AND SUPPORTIVE CARE 294

Chapter 9 TREATMENT STRATEGY 328

Chapter 10 COMMERCIAL ANALYSIS 401

Chapter 11 SUPPORTING DATA 414

Chapter 12 APPENDIX A 427

For more information visit http://www.researchandmarkets.com/reports/c8001

COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group